生物疫苗板塊走高 國產新冠滅活疫苗有望年底上市
格隆匯9月25日丨生物疫苗板塊拉昇走高,賽升藥業大漲超13%,康希諾漲近8%,瑞普生物、智飛生物、華蘭生物等跟漲。昨日,在第十三屆中國生物產業大會上,鍾南山院士表示,完成大規模接種疫苗需要1至2年的時間。目前,中國與40多個國家保持合作,並已經獲批在巴西、俄羅斯等國家開展III期臨牀試驗,4款疫苗已與國際合作進入III期臨牀試驗。國藥集團中國生物技術股份有限公司董事長楊曉明表示,新冠滅活疫苗目前試驗進展好於預期,快於預期,離最後成功還差“一公里”,2020年年底有望上市。目前,三個新冠滅活疫苗已經全部進入三期人體臨牀試驗。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.